

DR. DAVID LEBEAUX (Orcid ID : 0000-0002-7164-831X)

PROF. MAARTEN NAESENS (Orcid ID : 0000-0002-5625-0792)

PROF. NASSIM KAMAR (Orcid ID : 0000-0003-1930-8964)

Article type : Letter to the Editor

Transplant International, letter to the Editor

Autoantibodies against Granulocyte Macrophage Colony-Stimulating Factor and *Nocardia* infection in solid organ transplant recipients

David Lebeaux^{1,2,3} MD, Julien Coussement⁴ MD, Cécile Chauvet⁵ MD, Marie Matignon⁶ MD, Anne Scemla⁷ MD, Nicolas Bouvier⁸ MD, Jacques Dantal⁹ MD, Albert M. Vollaard¹⁰ MD, Herman F. Wunderink¹¹ MD, Eric Van Wijngaerden¹² MD, Maarten Naesens¹³ MD, Nassim Kamar¹⁴ MD, Julien De Greef¹⁵ MD, Romain Guillemain¹⁶ MD, Raphael Borie¹⁷ MD and Sophie Candon^{1,18*} MD.

Affiliations

¹ Université de Paris, F-75006 Paris.

² Service de Microbiologie, Unité Mobile d'Infectiologie, AP-HP, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France.

³ Université de Paris, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, Centre d'Infectiologie Necker-Pasteur and Institut Imagine, Paris, France

⁴ Department of Infectious Diseases, CUB-Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

⁵ Service de Transplantation Rénale , Hôpital Edouard HERRIOT, Lyon, France

⁶ Assistance Publique-Hôpitaux de Paris, Groupe Henri Mondor-Albert Chenevier, Nephrology and Transplantation Department, Centre d'Investigation Clinique-BioThérapies 504 and Institut National de la Santé et de la Recherche Médicale U955 and Paris Est University, Créteil, France

⁷ Kidney Transplantation Unit, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, RTRS Centaure, Labex Transplantex, Paris, France.

⁸ Service de Néphrologie, Université de Caen – Normandie, Caen, France

⁹ ITUN (Institut de Transplantation, d'Urologie et de Néphrologie), CHU Nantes, Nantes, France

¹⁰ Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

¹¹ Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/TRI.13727](#)

This article is protected by copyright. All rights reserved

¹² Department of microbiology, immunology and transplantation, KU Leuven, Leuven , Belgium

¹³ Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

¹⁴ Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse and INSERM U1043, IFR–BMT, CHU Purpan, Université Paul Sabatier, Toulouse, France

¹⁵ Service de Médecine interne et Maladies infectieuses, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium

¹⁶ Service d'Anesthésie-Réanimation, Hôpital Européen Georges Pompidou, Paris, France

¹⁷ Service de Pneumologie A, Hôpital Bichat, APHP, Paris, France et INSERM U1152, Paris, France

¹⁸ Immunologie Biologique, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, Paris France

*Current address: CHU de Rouen Normandie, Université de Rouen Normandie, Rouen France

Autorship

David Lebeaux designed and performed the study, collected and analyzed data and wrote the paper

Julien Coussement designed and performed the study, collected and analyzed data and wrote the paper

Cécile Chauvet collected data and wrote the paper

Marie Matignon collected data and wrote the paper

Anne Scemla collected data and wrote the paper

Nicolas Bouvier collected data and wrote the paper

Jacques Dantal collected data and wrote the paper

Albert M. Vollaard collected data and wrote the paper

Herman F. Wunderink collected data and wrote the paper

Eric Van Wijngaerden collected data and wrote the paper

Maarten Naesens collected data and wrote the paper

Nassim Kamar collected data and wrote the paper

Julien De Greef collected data and wrote the paper

Romain Guillemain collected data and wrote the paper

Raphael Borie collected and analyzed data and wrote the paper

Sophie Candon designed and performed the study, collected and analyzed data and wrote the paper

Funding sources

This work was supported by the « Bourse Junior 2015 – Société de Pathologie Infectieuse de Langue Française » (DL).

Corresponding author

David Lebeaux, Service de Microbiologie, Hôpital Européen Georges POMPIDOU, 20 rue Leblanc, 75015 PARIS.

Phone: +33 1.56.09.39.51. Fax: +33 1.56.09.24.46. E-mail: david.lebeaux@aphp.fr

Running title

Autoantibodies against GM-CSF and post-SOT nocardiosis

Abbreviations

Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)

Solid organ transplantation (SOT)

Conflict of interest statement

The authors declare no conflicts of interest.

Dear Editors,

Nocardiosis is a rare but potentially severe bacterial opportunistic infection that may occur after solid organ transplantation (SOT), typically among thoracic transplant recipients and/or in recipients with a high degree of immunosuppression due to anti-rejection therapy [1]. However, nocardiosis may also occur late after transplantation among minimally-immunosuppressed patients, suggesting that additional risk factors exist [1]. Recently, autoantibodies against Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) have been identified among five previously healthy patients with disseminated nocardiosis [2]. These autoantibodies likely promote nocardiosis by reducing neutrophil and macrophage activation, phagocytosis and bactericidal activity [2]. We hypothesized that anti-GM-CSF autoantibodies might be involved in post-SOT nocardiosis, especially in patients who apparently have a relatively low degree of immunosuppression.

We retrospectively analyzed sera from SOT recipients included in a European case-control study, and compared the prevalence of anti-GM-CSF autoantibodies between SOT recipients with nocardiosis (cases) and SOT recipients without nocardiosis (controls) [1]. Cases were SOT recipients who had a diagnosis of nocardiosis between 2000 and 2014. Matched control patients were SOT recipients who: (1) had received the same type of transplanted organ in the same institution as the case; (2) had received their transplant at about the same time as the case; (3) had no evidence of nocardiosis after transplant; (4) had survived as long as the case had prior to the diagnosis of nocardiosis. For cases, the date of diagnosis of nocardiosis was defined as the day on which the first clinical sample (e.g., sputum) yielding *Nocardia* spp. was collected. For control patients, a corresponding date was chosen on the basis of their matched case's date of diagnosis, in order to obtain a similar period of time from transplantation.

Specifically, we analyzed 56 sera sampled around the date of transplantation (+/- 1 month) (representing 17 cases and 39 controls) and 39 sera sampled around the date of *Nocardia* infection (+/- 6 months) (representing 14 cases and 25 controls). Characteristics of included cases and controls are summarized in **Table 1**.

None of the patients exhibited a significant level of autoantibodies against GM-CSF, suggesting that these antibodies are not associated with nocardiosis in SOT recipients (**Figure 1**). The physiopathology of post-transplant nocardiosis remains poorly understood, and it is unclear why nocardiosis sometimes occur late after transplantation among minimally-immunosuppressed SOT recipients. It remains possible that occult immune defect(s) increase the susceptibility to nocardiosis after transplantation. There is a need for a simple, functional test to predict the risk of nocardiosis (and other opportunistic infections) in SOT recipients. It is also possible that environmental factors play an important role in the occurrence of *Nocardia* infection after SOT, given that *Nocardia* spp. can be found in a variety of environments such as dust, soil, decaying vegetation, and water.

REFERENCES

1. Coussement J, Lebeaux D, van Delden C, et al. *Nocardia* infection in solid organ transplant recipients: a multicenter European case-control study. Clin Infect Dis **2016**; 63(3): 338-45.
2. Rosen LB, Rocha Pereira N, Figueiredo C, et al. *Nocardia*-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis. Clin Infect Dis **2015**; 60(7): 1017-25.
3. Uchida K, Nakata K, Carey B, et al. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods **2014**; 402(1-2): 57-70.

TABLE AND FIGURE

Table 1. Clinical and biological characteristics of 22 nocardiosis cases and 45 matched controls for whom at least one serum sample has been stored and analyzed to investigate the presence of anti-GM-CSF autoantibodies.

Characteristics	Cases (n=22)	Controls (n=45)
Clinical characteristics		
Age at diagnosis (years) (mean $\pm$ SD)	57 $\pm$ 16	50 $\pm$ 14
Male	16 (70)	29 (60)
Donor age (mean $\pm$ SD) n=63	48 $\pm$ 19	46 $\pm$ 18
Length of stay in the intensive care unit after transplantation (days) (mean $\pm$ SD)	6 $\pm$ 10	6 $\pm$ 9
Transplanted organ		
Kidney	17 (77)	34 (75)
Heart or lung	1 (5)	3 (7)
Chronic obstructive pulmonary disease after transplant	2 (10)	1 (2)
Acute rejection episode in the 6 months before diagnosis of nocardiosis	4 (20)	4 (10)
Cytomegalovirus infection in the 6 months before diagnosis of nocardiosis	3 (10)	1 (2)
Cytomegalovirus disease in the 6 months before diagnosis of nocardiosis	1 (5)	1 (2)
Bloodstream infection before diagnosis of nocardiosis	3 (10)	5 (10)
Therapeutic characteristics		
Dose of corticosteroids at diagnosis of nocardiosis (mg ⁺) (mean $\pm$ SD)	7 $\pm$ 3	5 $\pm$ 3
High-dose steroids in the 6 months before diagnosis of nocardiosis	4 (20)	4 (10)
Cyclosporin at diagnosis of nocardiosis	3 (10)	10 (20)
Tacrolimus at diagnosis of nocardiosis	19 (90)	30 (70)
High calcineurin inhibitor blood level in the month before diagnosis of nocardiosis*	8 (40)	5 (10)
Use of antiproliferative agents (AZA or MMF) at diagnosis	18 (82)	40 (89)
Use of triple immunosuppression [§] at diagnosis	17 (77)	26 (58)
Cotrimoxazole prophylaxis at diagnosis of nocardiosis	5 (20)	5 (10)
Biological characteristics		
WBC count 1 month before diagnosis of nocardiosis (x1000/ μ l) (mean $\pm$ SD) n=64	10.0 $\pm$ 4.2	7.2 $\pm$ 2.5
Lymphocyte count at 2 months post-transplant (x1000/ μ l) (mean $\pm$ SD) n=59	0.9 $\pm$ 0.7	1.0 $\pm$ 0.7
Lymphocyte count 1 month before diagnosis of nocardiosis (x1000/ μ l) (mean $\pm$ SD) n=60	0.8 $\pm$ 0.5	1.6 $\pm$ 1.1
Neutrophil count 1 month before diagnosis of nocardiosis (x1000/ μ l) (mean $\pm$ SD) n=60	8.3 $\pm$ 4.1	5.2 $\pm$ 2.0
Nocardiosis characteristics		
Time from transplantation to diagnosis of nocardiosis (months) (median, range)	17 [1-171]	NA
Involved organs		
Lung	19 (90)	NA
Skin and soft-tissue	8 (40)	NA
Brain	4 (20)	NA

Disseminated infection	9 (40)	NA
Patient outcomes		
Relapse of nocardiosis	2 (10)	NA
Alive 12 months after diagnosis of nocardiosis	21 (95)	NA

NOTE. Data are n (%) unless otherwise indicated. n: number of data analyzed (when <67).


AZA: azathioprine; MMF: mycophenolate mofetil; NA: not applicable; SD: standard deviation; WBC: white blood cell.

†All the corticosteroid doses are expressed in milligrams (mg) of methylprednisolone equivalent per day.

*High calcineurin inhibitor level was defined as a trough blood level >10 µL/mL for tacrolimus and >300 ng/mL for cyclosporine.

§ Tripe immunosuppression was defined as the combination of corticosteroids, calcineurin inhibitor and antiproliferative agent

Figure 1. Detection of anti-GM-CSF autoantibodies among nocardiosis cases, matched transplanted controls, healthy controls and patients with pulmonary alveolar proteinosis (PAP). Sera from nocardiosis cases were sampled around the transplantation date (Tx) or around the date of nocardiosis diagnosis (Noc). Comparisons between groups were performed using Mann-Whitney-Wilcoxon test in Prism® (Graphpad). *** $p < 0.0001$. * $p = 0.034$. OD: Optical density. The presence of anti-GM-CSF antibodies was determined using a previously described ELISA assay [3]. For controls, we used four sera from patients with acquired PAP – i.e., a pulmonary disease induced by anti-GM-CSF autoantibodies – (positive controls), and ten sera from healthy adult subjects (negative controls). Results were expressed as an OD ratio: mean optical absorbance of the 1/100 diluted sample divided by mean absorbance of a 1/100 diluted negative control. Results for PAP samples were expressed as the mean absorbance of the 1/1000 dilution divided by the mean absorbance of the 1/100 diluted negative control, and then multiplied by 10. The dotted line represents the positivity threshold of the assay (6.1 OD ratio) as defined by a receiver operating characteristic (ROC) analysis of values in controls and PAP patients. At this threshold, the sensitivity and specificity of the assay are 100% and 98.7%, respectively.



tri_13727_f1.jpg